Reblozyl(luspatercept)
Reblozyl (luspatercept) is a protein pharmaceutical. Luspatercept was first approved as Reblozyl on 2019-11-08. It is used to treat anemia in the USA. It has been approved in Europe to treat anemia, beta-thalassemia, and myelodysplastic syndromes. It is known to target growth/differentiation factor 11, bone morphogenetic protein 10, growth/differentiation factor 2, growth/differentiation factor 8, and bone morphogenetic protein 6.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Reblozyl
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| luspatercept | Biologic Licensing Application | 2019-11-18 |
| reblozyl | Biologic Licensing Application | 2024-05-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| anemia | HP_0001903 | D000740 | D64.9 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
luspatercept, Reblozyl, Celgene Corporation, a Bristol-Myers Squibb Company | |||
| 2030-08-28 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0896 | Injection, luspatercept-aamt, 0.25 mg |
Clinical
Clinical Trials
45 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 2 | 2 | 1 | 2 | 7 |
| Preleukemia | D011289 | — | — | — | 1 | 2 | 1 | 2 | 6 |
| Thalassemia | D013789 | EFO_1001996 | D56 | — | 2 | — | 1 | 2 | 5 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | 2 | 1 | 1 | — | 4 |
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | 1 | — | 1 | 2 | 4 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Luspatercept |
| INN | luspatercept |
| Description | Luspatercept |
| Classification | Protein |
| Drug class | receptor molecules or membrane ligands, natural, modified or modified: transforming growth factor receptors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1373715-00-4 |
| RxCUI | 2262544 |
| ChEMBL ID | CHEMBL3039545 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12281 |
| UNII ID | AQK7UBA1LS (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GDF11
GDF11
BMP10
BMP10
GDF2
GDF2
MSTN
MSTN
BMP6
BMP6
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Reblozyl – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Reblozyl – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 683 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,426 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use